Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCENESSE plus NB-UVB versus NB-UVB alone for vitiligo
2023-507470-40-00Phase 3Authorised
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Aug 2024
- Modality
- Small Molecules, Peptides
- Countries
- 6
01
Overview
Phase 3, open-label trial of Afamelanotide in Vitiligo (2 arms), sponsored by Clinuvel Pharmaceuticals. Primary endpoint: Percentage of participants achieving repigmentation. Planned start Aug 2024; status: authorised.
02
Drugs
Afamelanotide
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2023-507470-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507470-40-00.